Faes Farma (FAE) CMD 2025 summary

Strategic vision and leadership

• New CEO Eduardo Recoder brings over 20 years of global pharma experience, aiming to accelerate growth and international expansion.

• Faes Farma has evolved from a national to a global company, consolidating its presence in new markets, especially LATAM.

• The company has a solid financial base, with revenues growing from €198M in 2014 to €510M in 2024, and international revenues now representing 57% of the total.

• The workforce is diverse and global, with 1,775 employees across 130+ countries and a balanced gender split.

Strategic plan 2025–2030: transforming the future

• The new plan is built on four pillars: accelerating growth, leading from science, achieving commercial and operational excellence, and promoting positive impact.

• Ambition to double sales and EBITDA by 2030, targeting €815–845M in revenues and €190–200M in EBITDA, with a CAGR of 11–12% and 10–11% respectively (including M&A).

• Organic growth will be driven by international pharma sales, especially in LATAM and the Gulf, with M&A as a key accelerator.

• The acquisition of Edol strengthens the ophthalmology portfolio and doubles sales and EBITDA in Portugal.

• R&D investment will rise from 6% to 10% of pharma sales by 2030, with over €25M invested in 2024 and 15 strategic launches planned for 2025–2030.

Growth levers and business development

• Pharma business will focus on innovation in Iberia, international expansion in LATAM and the Gulf, and portfolio diversification through licensing.

• International pharma revenues are expected to double by 2030, reaching €295–305M, and represent 30% of group sales.

• FARM Faes (animal nutrition) aims to double revenues by 2027–2028 through internationalisation, diversification, and vertical integration.

• M&A targets include companies with innovative products in high-growth therapeutic areas and advanced emerging markets, aiming to add ~€170M in sales by 2030.

• The new Derio plant will centralise production, double capacity, and support operational excellence and margin improvement.